EAM
NKGN

Exos Asset Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Exos Asset Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$699K Buy
+71,939
New +$700K 0.36% 87
2022
Q1 		– Sell
-70,000
Closed -$678K – 331
2021
Q4 		$678K Hold
70,000
– – 0.35% 96
2021
Q3 		$678K Buy
+70,000
New +$683K 0.36% 84

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Exos Asset Management's NKGN Position: Q2 2022 in Review

Exos Asset Management opened a new position in NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2022: 71,939 shares worth $699K. The stake represents 0.36% of the portfolio and ranks #87 among its holdings. This is a return to the name: Exos Asset Management previously reported a position in NKGN as recently as Q4 2021.

Exos Asset Management first reported a position in NKGN in Q3 2021 and has held it in 3 quarters since. 48 funds tracked by Wall St. Rank hold NKGN as of Q2 2022.

  • Exos Asset Management held 71,939 shares of NKGen Biotech, Inc. Common Stock worth $699K as of Q2 2022.
  • NKGen Biotech, Inc. Common Stock was a new Exos Asset Management position in Q2 2022.
  • NKGen Biotech, Inc. Common Stock made up 0.36% of Exos Asset Management's portfolio in Q2 2022, its #87 holding.
  • Exos Asset Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and has held it in 3 quarters since.
  • 48 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2022.

Based on Exos Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.